Splenic iron decreases without change in volume or liver parameters during luspatercept therapy.

Denton, Christopher C; Vodala, Sadanand; Veluswamy, Saranya; Hofstra, Thomas C; Coates, Thomas D; Wood, John C

Denton, Christopher C; Vodala, Sadanand; Veluswamy, Saranya; Hofstra, Thomas C; Coates, Thomas D; Wood, John C.

Afiliación

Denton CC; Division of Hematology/Oncology, Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA.
Vodala S; Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Veluswamy S; Bristol Myers Squibb, Summit, NJ.
Hofstra TC; Division of Hematology/Oncology, Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA.
Coates TD; Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Wood JC; Division of Hematology/Oncology, Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA.

Blood ; 142(22): 1932-1934, 2023 11 30.

Article en En | MEDLINE | ID: mdl-37704579

Asunto(s)

Hierro; Talasemia beta; Humanos; Receptores de Activinas Tipo II; Talasemia beta/tratamiento farmacológico; Eritropoyesis; Hígado

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Talasemia beta / Hierro Límite: Humans Idioma: En Revista: Blood Año: 2023 Tipo del documento: Article País de afiliación: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google